Skip to main content
Top
Published in: BMC Nephrology 1/2013

Open Access 01-12-2013 | Research article

Metabolic syndrome, C-reactive protein and microalbuminuria in a rural Chinese population: a cross-sectional study

Authors: Liping Jiang, Wen Huang, Yuanbo Liang, Fenghua Wang, Xinrong Duan, Xiaohui Yang, Jiangping Wen, Ningli Wang

Published in: BMC Nephrology | Issue 1/2013

Login to get access

Abstract

Background

Microalbuminuria is an early marker of chronic kidney disease (CKD). Previous studies have shown that either metabolic syndrome (MetS) or chronic inflammation is related to renal impairment. The aim of this study was to investigate the association between MetS, C-reactive protein (CRP) and microalbuminuria in a rural Chinese population.

Methods

This was a cross-sectional study using data from the Handan Eye Study. MetS was defined according to the Chinese Diabetes Society (CDS) criteria. CRP levels ≥ 3 mg/L were classified as high CRP. Microalbuminuria was defined as a urinary albumin/creatinine ratio (ACR) of 30–300 mg/g.

Results

We included 4191 subjects aged ≥ 30 years in this analysis. The prevalence of MetS and microalbuminuria in the group was 25.7% and 15.6%, respectively. The odds ratio (OR) of microalbuminuria in subjects with MetS was 1.25 (95% confidence interval (CI): 1.03 − 1.51) compared with those without microalbuminuria. In multivariate logistic regression analysis, high blood pressure (OR 1.36, 95% CI: 1.10 − 1.67) and high fasting blood glucose (OR 1.44, 95% CI: 1.17 − 1.76) were independently associated with microalbuminuria. Subjects with high CRP and MetS had a 1.46-fold greater risk of having microalbuminuria compared with those with low CRP without MetS (95% CI: 1.06 − 2.01).

Conclusions

In this rural Chinese population aged ≥30 years, MetS and microalbuminuria were independently related and the combination of high CRP and MetS was associated with an increased risk of microalbuminuria.
Literature
1.
go back to reference Gerstein HC, Mann JF, Yi Q: Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and nondiabetic individuals. JAMA. 2001, 286: 421-426. 10.1001/jama.286.4.421.CrossRefPubMed Gerstein HC, Mann JF, Yi Q: Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and nondiabetic individuals. JAMA. 2001, 286: 421-426. 10.1001/jama.286.4.421.CrossRefPubMed
2.
go back to reference Pinto-Sietsma SJ, Janssen WM, Hillege HL: Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. J Am Soc Nephrol. 2000, 11: 1882-1888.PubMed Pinto-Sietsma SJ, Janssen WM, Hillege HL: Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. J Am Soc Nephrol. 2000, 11: 1882-1888.PubMed
3.
go back to reference Pedrinelli R, Dell’Omo G, Di Bello V: Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens. 2002, 16: 79-89. 10.1038/sj.jhh.1001316.CrossRefPubMed Pedrinelli R, Dell’Omo G, Di Bello V: Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens. 2002, 16: 79-89. 10.1038/sj.jhh.1001316.CrossRefPubMed
4.
go back to reference Hillege HL, Fidler V, Diercks GF: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002, 106: 1777-1782. 10.1161/01.CIR.0000031732.78052.81.CrossRefPubMed Hillege HL, Fidler V, Diercks GF: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002, 106: 1777-1782. 10.1161/01.CIR.0000031732.78052.81.CrossRefPubMed
5.
go back to reference Solbu MD, Kronborg J, Jenssen TG: Albuminuria, metabolic syndrome and the risk of mortality and cardiovascular events. Atherosclerosis. 2009, 204: 503-508. 10.1016/j.atherosclerosis.2008.11.002.CrossRefPubMed Solbu MD, Kronborg J, Jenssen TG: Albuminuria, metabolic syndrome and the risk of mortality and cardiovascular events. Atherosclerosis. 2009, 204: 503-508. 10.1016/j.atherosclerosis.2008.11.002.CrossRefPubMed
6.
go back to reference Palmer AJ, Roze S, Rodby RA: Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy. Dtsch Med Wochenschr. 2006, 131: 1721-1726. 10.1055/s-2006-947822.CrossRefPubMed Palmer AJ, Roze S, Rodby RA: Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy. Dtsch Med Wochenschr. 2006, 131: 1721-1726. 10.1055/s-2006-947822.CrossRefPubMed
7.
go back to reference Gu D, Reynolds K, Wu X: Prevalence of the metabolic syndrome and overweight among adults in China. Lancet. 2005, 365: 1398-1405. 10.1016/S0140-6736(05)66375-1.CrossRefPubMed Gu D, Reynolds K, Wu X: Prevalence of the metabolic syndrome and overweight among adults in China. Lancet. 2005, 365: 1398-1405. 10.1016/S0140-6736(05)66375-1.CrossRefPubMed
8.
go back to reference Palaniappan L, Carnethon M, Fortmann SP: Association between microalbuminuria and the metabolic syndrome: NHANESIII. Am J Hypertens. 2003, 16: 952-958. 10.1016/S0895-7061(03)01009-4.CrossRefPubMed Palaniappan L, Carnethon M, Fortmann SP: Association between microalbuminuria and the metabolic syndrome: NHANESIII. Am J Hypertens. 2003, 16: 952-958. 10.1016/S0895-7061(03)01009-4.CrossRefPubMed
9.
go back to reference Hao Z, Konta T, Takasaki S: The association between microalbuminuria and metabolic syndrome in the general population in Japan: the Takahata study. Inter Med. 2007, 46: 341-346. 10.2169/internalmedicine.46.6056.CrossRef Hao Z, Konta T, Takasaki S: The association between microalbuminuria and metabolic syndrome in the general population in Japan: the Takahata study. Inter Med. 2007, 46: 341-346. 10.2169/internalmedicine.46.6056.CrossRef
10.
go back to reference Lin CC, Liu CS, Li TC: Microalbuminuria and the metabolic syndrome and its components in the Chinese population. Eur J Clin Invest. 2007, 37: 783-790. 10.1111/j.1365-2362.2007.01865.x.CrossRefPubMed Lin CC, Liu CS, Li TC: Microalbuminuria and the metabolic syndrome and its components in the Chinese population. Eur J Clin Invest. 2007, 37: 783-790. 10.1111/j.1365-2362.2007.01865.x.CrossRefPubMed
11.
go back to reference Kshirsagar AV, Bomback AS, Bang H: Association of C-reactive protein and microalbuminuria (from the National Health and Nutrition Examination Surveys, 1999 to 2004). Am J Cardiol. 2008, 101: 401-406. 10.1016/j.amjcard.2007.08.041.CrossRefPubMed Kshirsagar AV, Bomback AS, Bang H: Association of C-reactive protein and microalbuminuria (from the National Health and Nutrition Examination Surveys, 1999 to 2004). Am J Cardiol. 2008, 101: 401-406. 10.1016/j.amjcard.2007.08.041.CrossRefPubMed
12.
go back to reference Nakamura M, Onoda T, Itai K: Association between serum C-reactive protein levels and microalbuminuria: a population-based cross-sectional study in northern Iwate, Japan. Intern Med. 2004, 43: 919-925. 10.2169/internalmedicine.43.919.CrossRefPubMed Nakamura M, Onoda T, Itai K: Association between serum C-reactive protein levels and microalbuminuria: a population-based cross-sectional study in northern Iwate, Japan. Intern Med. 2004, 43: 919-925. 10.2169/internalmedicine.43.919.CrossRefPubMed
13.
go back to reference Fox ER, Benjamin EJ, Sarpong DF: The relation of C-reactive protein to chronic kidney disease in African Americans:the Jackson Heart Study. BMC Nephrol. 2010, 11: 1-10.1186/1471-2369-11-1.CrossRefPubMedPubMedCentral Fox ER, Benjamin EJ, Sarpong DF: The relation of C-reactive protein to chronic kidney disease in African Americans:the Jackson Heart Study. BMC Nephrol. 2010, 11: 1-10.1186/1471-2369-11-1.CrossRefPubMedPubMedCentral
14.
go back to reference Festa A, D'Agostino RD, Howard G: Inflammation and microalbuminuria in nondiabetic and type 2diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int. 2000, 58: 1703-1710. 10.1046/j.1523-1755.2000.00331.x.CrossRefPubMed Festa A, D'Agostino RD, Howard G: Inflammation and microalbuminuria in nondiabetic and type 2diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int. 2000, 58: 1703-1710. 10.1046/j.1523-1755.2000.00331.x.CrossRefPubMed
15.
go back to reference Jiang L, Liang Y, Qiu B: Prevalence of chronic kidney disease in a rural Chinese adult population: the Handan Eye Study. Nephron Clin Pract. 2010, 114: 295-302. 10.1159/000276582.CrossRef Jiang L, Liang Y, Qiu B: Prevalence of chronic kidney disease in a rural Chinese adult population: the Handan Eye Study. Nephron Clin Pract. 2010, 114: 295-302. 10.1159/000276582.CrossRef
16.
go back to reference Liang YB, Friedman DS, Wong TY: Prevalence and cause of low vision and blindness in a rural Chinese adult population: the handan eye study. Ophthalmology. 2008, 115: 1965-1972. 10.1016/j.ophtha.2008.05.030.CrossRefPubMed Liang YB, Friedman DS, Wong TY: Prevalence and cause of low vision and blindness in a rural Chinese adult population: the handan eye study. Ophthalmology. 2008, 115: 1965-1972. 10.1016/j.ophtha.2008.05.030.CrossRefPubMed
17.
go back to reference Expert Panel on Metabolic Syndrome of Chinese Diabetes Society: Recommendations on metabolic syndrome of Chinese Diabetes Society (Chinese). Chin J Diabetes. 2004, 12: 156-161. Expert Panel on Metabolic Syndrome of Chinese Diabetes Society: Recommendations on metabolic syndrome of Chinese Diabetes Society (Chinese). Chin J Diabetes. 2004, 12: 156-161.
18.
go back to reference Grundy SM, Cleeman JI, Daniels SR: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005, 112: 2735-2752. 10.1161/CIRCULATIONAHA.105.169404.CrossRefPubMed Grundy SM, Cleeman JI, Daniels SR: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005, 112: 2735-2752. 10.1161/CIRCULATIONAHA.105.169404.CrossRefPubMed
19.
go back to reference Pearson TA, Mensah GA, Alexander RW: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003, 107: 499-511. 10.1161/01.CIR.0000052939.59093.45.CrossRefPubMed Pearson TA, Mensah GA, Alexander RW: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003, 107: 499-511. 10.1161/01.CIR.0000052939.59093.45.CrossRefPubMed
20.
go back to reference Levey AS, Coresh J, Balk E: National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003, 139: 137-147. 10.7326/0003-4819-139-2-200307150-00013.CrossRefPubMed Levey AS, Coresh J, Balk E: National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003, 139: 137-147. 10.7326/0003-4819-139-2-200307150-00013.CrossRefPubMed
21.
go back to reference Zhang L, Zuo L, Wang F: Metabolic syndrome and chronic kidney disease in a Chinese population aged 40 years and older. Mayo Clin Proc. 2007, 82: 822-827. 10.4065/82.7.822.CrossRefPubMed Zhang L, Zuo L, Wang F: Metabolic syndrome and chronic kidney disease in a Chinese population aged 40 years and older. Mayo Clin Proc. 2007, 82: 822-827. 10.4065/82.7.822.CrossRefPubMed
22.
go back to reference Chen W, Chen W, Wang H: Prevalence and risk factors associated with chronic kidney disease in an adult population from southern China. Nephrol Dial Transplant. 2009, 24: 1205-1212.CrossRefPubMed Chen W, Chen W, Wang H: Prevalence and risk factors associated with chronic kidney disease in an adult population from southern China. Nephrol Dial Transplant. 2009, 24: 1205-1212.CrossRefPubMed
23.
go back to reference Li Q, Jia WP, Lu JQ: Relationship between the prevalence of microalbuminuria and components of metabolic syndrome in Shanghai. Clin J Epidemiol. 2004, 25: 65-68. Li Q, Jia WP, Lu JQ: Relationship between the prevalence of microalbuminuria and components of metabolic syndrome in Shanghai. Clin J Epidemiol. 2004, 25: 65-68.
24.
go back to reference Chen B, Yang D, Chen Y: The prevalence of microalbuminuria and its relationships with the components of metabolic syndrome in the general population of China. Clin Chim Acta. 2010, 411: 705-709. 10.1016/j.cca.2010.01.038.CrossRefPubMed Chen B, Yang D, Chen Y: The prevalence of microalbuminuria and its relationships with the components of metabolic syndrome in the general population of China. Clin Chim Acta. 2010, 411: 705-709. 10.1016/j.cca.2010.01.038.CrossRefPubMed
25.
go back to reference Raimundo M, Lopes JA: Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease: A Dynamic and Life-Threatening Triad. Cardiol Res Pract. 2011, 2011: 747-861. Raimundo M, Lopes JA: Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease: A Dynamic and Life-Threatening Triad. Cardiol Res Pract. 2011, 2011: 747-861.
26.
go back to reference Fröhlich M, Imhof A, Berg G: Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care. 2000, 23: 1835-1839. 10.2337/diacare.23.12.1835.CrossRefPubMed Fröhlich M, Imhof A, Berg G: Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care. 2000, 23: 1835-1839. 10.2337/diacare.23.12.1835.CrossRefPubMed
27.
go back to reference Beddhu S, Kimmel PL, Ramkumar N, Cheung AK: Associations of metabolic syndrome with inflammation in CKD: results From the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2005, 46: 577-586. 10.1053/j.ajkd.2005.06.014.CrossRefPubMed Beddhu S, Kimmel PL, Ramkumar N, Cheung AK: Associations of metabolic syndrome with inflammation in CKD: results From the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2005, 46: 577-586. 10.1053/j.ajkd.2005.06.014.CrossRefPubMed
28.
go back to reference Ye X, Yu Z, Li H: Distributions of C-reactive protein and its association with metabolic syndrome in middle aged and older Chinese people. J Am Coll Cardiol. 2007, 49: 1798-1805. 10.1016/j.jacc.2007.01.065.CrossRefPubMed Ye X, Yu Z, Li H: Distributions of C-reactive protein and its association with metabolic syndrome in middle aged and older Chinese people. J Am Coll Cardiol. 2007, 49: 1798-1805. 10.1016/j.jacc.2007.01.065.CrossRefPubMed
29.
go back to reference Wen J, Liang Y, Wang F: Association of C-reactive protein and metabolic syndrome in a rural Chinese population. Clin Biochem. 2009, 42: 976-983. 10.1016/j.clinbiochem.2009.03.026.CrossRefPubMed Wen J, Liang Y, Wang F: Association of C-reactive protein and metabolic syndrome in a rural Chinese population. Clin Biochem. 2009, 42: 976-983. 10.1016/j.clinbiochem.2009.03.026.CrossRefPubMed
30.
go back to reference Sabanayagam C, Lee J, Shankar A: C-reactive protein and microalbuminuria in a multi- ethnic Asian population. Nephrol Dial Transplant. 2010, 25: 1167-1172. 10.1093/ndt/gfp591.CrossRefPubMed Sabanayagam C, Lee J, Shankar A: C-reactive protein and microalbuminuria in a multi- ethnic Asian population. Nephrol Dial Transplant. 2010, 25: 1167-1172. 10.1093/ndt/gfp591.CrossRefPubMed
31.
go back to reference Fakhrzadeh H, Ghaderpanahi M, Sharifi F: Increased risk of chronic kidney disease in elderly with metabolic syndrome and high levels of C-reactive protein: Kahrizak Elderly Study. Kidney Blood Press Res. 2009, 32: 457-463. 10.1159/000274046.CrossRefPubMed Fakhrzadeh H, Ghaderpanahi M, Sharifi F: Increased risk of chronic kidney disease in elderly with metabolic syndrome and high levels of C-reactive protein: Kahrizak Elderly Study. Kidney Blood Press Res. 2009, 32: 457-463. 10.1159/000274046.CrossRefPubMed
32.
go back to reference Lee JE, Choi SY, Huh W: Metabolic syndrome, C-reactive protein, and chronic kidney disease in nondiabetic, nonhypertensive adults. Am J Hypertens. 2007, 20: 1189-1194.PubMed Lee JE, Choi SY, Huh W: Metabolic syndrome, C-reactive protein, and chronic kidney disease in nondiabetic, nonhypertensive adults. Am J Hypertens. 2007, 20: 1189-1194.PubMed
33.
go back to reference Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE Investigators: Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation / CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001, 286: 64-70. 10.1001/jama.286.1.64.CrossRefPubMed Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE Investigators: Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation / CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001, 286: 64-70. 10.1001/jama.286.1.64.CrossRefPubMed
34.
go back to reference Nissen SE, Tuzcu EM, Schoenhagen P: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005, 352: 29-38. 10.1056/NEJMoa042000.CrossRefPubMed Nissen SE, Tuzcu EM, Schoenhagen P: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005, 352: 29-38. 10.1056/NEJMoa042000.CrossRefPubMed
Metadata
Title
Metabolic syndrome, C-reactive protein and microalbuminuria in a rural Chinese population: a cross-sectional study
Authors
Liping Jiang
Wen Huang
Yuanbo Liang
Fenghua Wang
Xinrong Duan
Xiaohui Yang
Jiangping Wen
Ningli Wang
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2013
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-14-118

Other articles of this Issue 1/2013

BMC Nephrology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine